Huntington National Bank’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$514K Sell
10,727
-1,490
-12% -$64K ﹤0.01% 658
2026
Q1
$449K Sell
12,217
-2,059
-14% -$97.6K ﹤0.01% 661
2025
Q4
$726K Sell
14,276
-3,058
-18% -$156K ﹤0.01% 490
2025
Q3
$962K Sell
17,334
-526
-3% -$30.8K 0.01% 450
2025
Q2
$1.23M Sell
17,860
-366
-2% -$24.9K 0.01% 410
2025
Q1
$1.27M Sell
18,226
-2,801
-13% -$231K 0.01% 397
2024
Q4
$1.81M Buy
21,027
+2,818
+15% +$305K 0.01% 343
2024
Q3
$2.17M Buy
18,209
+2,065
+13% +$275K 0.02% 328
2024
Q2
$2.3M Sell
16,144
-236
-1% -$31.3K 0.02% 306
2024
Q1
$2.1M Buy
16,380
+1,335
+9% +$159K 0.02% 322
2023
Q4
$1.56M Sell
15,045
-2,380
-14% -$235K 0.01% 352
2023
Q3
$1.58M Buy
17,425
+4,085
+31% +$360K 0.02% 338
2023
Q2
$1.08M Buy
13,340
+2,824
+27% +$231K 0.01% 381
2023
Q1
$837K Buy
10,516
+358
+4% +$25.4K 0.01% 404
2022
Q4
$687K Sell
10,158
-1,346
-12% -$78.9K 0.01% 425
2022
Q3
$573K Sell
11,504
-1,712
-13% -$91.7K 0.01% 436
2022
Q2
$736K Buy
13,216
+74
+0.6% +$4.11K 0.01% 413
2022
Q1
$729K Sell
13,142
-552
-4% -$28.3K 0.01% 429
2021
Q4
$767K Buy
13,694
+1,520
+12% +$82.3K 0.01% 427
2021
Q3
$585K Buy
12,174
+194
+2% +$9.38K 0.01% 453
2021
Q2
$501K Sell
11,980
-340
-3% -$13.2K 0.01% 479
2021
Q1
$415K Buy
12,320
+1,556
+14% +$55.4K 0.01% 420
2020
Q4
$376K Sell
10,764
-1,284
-11% -$44.4K ﹤0.01% 417
2020
Q3
$418K Sell
12,048
-38
-0.3% -$1.27K 0.01% 392
2020
Q2
$396K Sell
12,086
-1,600
-12% -$51.1K 0.01% 398
2020
Q1
$412K Sell
13,686
-740
-5% -$22K 0.01% 382
2019
Q4
$417K Buy
14,426
+3,484
+32% +$96.5K 0.01% 425
2019
Q3
$283K Sell
10,942
-2,272
-17% -$57.5K ﹤0.01% 464
2019
Q2
$337K Sell
13,214
-528
-4% -$13K 0.01% 440
2019
Q1
$359K Sell
13,742
-364
-3% -$8.95K 0.01% 431
2018
Q4
$325K Sell
14,106
-3,106
-18% -$69K 0.01% 440
2018
Q3
$405K Sell
17,212
-1,930
-10% -$47.1K 0.01% 437
2018
Q2
$441K Sell
19,142
-132
-0.7% -$3.14K 0.01% 424
2018
Q1
$475K Sell
19,274
-116
-0.6% -$3.05K 0.01% 427
2017
Q4
$520K Sell
19,390
-552
-3% -$14K 0.01% 421
2017
Q3
$481K Sell
19,942
-336
-2% -$7.59K 0.01% 434
2017
Q2
$435K Sell
20,278
-15,928
-44% -$321K 0.01% 445
2017
Q1
$620K Buy
36,206
+19,714
+120% +$343K 0.01% 423
2016
Q4
$296K Sell
16,492
-3,766
-19% -$68.3K 0.01% 530
2016
Q3
$421K Sell
20,258
-344
-2% -$8.53K 0.01% 468
2016
Q2
$554K Sell
20,602
-7,170
-26% -$197K 0.01% 367
2016
Q1
$741K Buy
27,772
+4,548
+20% +$122K 0.02% 383
2015
Q4
$674K Sell
23,224
-390
-2% -$10.8K 0.02% 362
2015
Q3
$640K Sell
23,614
-1,764
-7% -$49.9K 0.02% 379
2015
Q2
$695K Sell
25,378
-2,394
-9% -$67.3K 0.02% 379
2015
Q1
$741K Sell
27,772
-6,642
-19% -$153K 0.02% 383
2014
Q4
$728K Sell
34,414
-22,272
-39% -$497K 0.02% 383
2014
Q3
$1.35M Sell
56,686
-4,318
-7% -$99.4K 0.03% 458
2014
Q2
$1.41M Sell
61,004
-18,500
-23% -$408K 0.03% 494
2014
Q1
$1.81M Buy
79,504
+12,504
+19% +$266K 0.03% 460
2013
Q4
$1.24M Sell
67,000
-4,740
-7% -$82.6K 0.03% 302
2013
Q3
$1.21M Sell
71,740
-1,620
-2% -$27.2K 0.04% 290
2013
Q2
$1.14M Buy
+73,360
New +$1.22M 0.04% 291

Other funds holding NVO

Huntington National Bank's NVO Position: Q2 2026 in Review

Huntington National Bank reduced its Novo Nordisk (NVO) stake by 12% in Q2 2026, selling an estimated $64K and leaving 10,727 shares worth $514K. The position accounts for ﹤0.01% of the portfolio, ranked #658.

Huntington National Bank first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.3M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Huntington National Bank held 10,727 shares of Novo Nordisk worth $514K as of Q2 2026.
  • Huntington National Bank sold 1,490 Novo Nordisk shares in Q2 2026, an estimated $64K.
  • Novo Nordisk made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #658 holding.
  • Huntington National Bank first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Huntington National Bank's Novo Nordisk position peaked at $2.3M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.